February 24, 2022 -- Moderna and Thermo Fisher Scientific have entered into a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.
Over the past several years, Thermo Fisher has been partnering with Moderna to support its development pipeline with both clinical research and contract manufacturing services. This included the quick scale-up of aseptic fill-finish services and packaging of its COVID-19 vaccine. As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling. In addition, the company will provide inspection, labeling and final packaging services.
Moderna is a biotechnology company pioneering mRNA therapeutics and vaccines. Thermo Fisher Scientific is renowned for serving science.
No financial details were disclosed.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
